Baxalta Company Profile (NYSE:BXLT)

About Baxalta (NYSE:BXLT)

Baxalta logoBaxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta's categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NYSE:BXLT
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $46.02
  • 200 Day Moving Avg: $46.02
  • 52 Week Range: $37.44 - $46.52
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 18.12
  • P/E Growth: 0.00

Frequently Asked Questions for Baxalta (NYSE:BXLT)

What is Baxalta's stock symbol?

Baxalta trades on the New York Stock Exchange (NYSE) under the ticker symbol "BXLT."

How were Baxalta's earnings last quarter?

Baxalta Inc (NYSE:BXLT) released its quarterly earnings results on Thursday, April, 28th. The company reported $0.47 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.46 by $0.01. The business had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.47 billion. The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.40 earnings per share. View Baxalta's Earnings History.

Who are some of Baxalta's key competitors?

Who owns Baxalta stock?

Baxalta's stock is owned by a number of of institutional and retail investors. Top institutional investors include Tompkins Financial Corp (0.00%). Company insiders that own Baxalta stock include Albert P L Stroucken and Blake E Devitt. View Institutional Ownership Trends for Baxalta.

Who bought Baxalta stock? Who is buying Baxalta stock?

Baxalta's stock was acquired by a variety of institutional investors in the last quarter, including Tompkins Financial Corp. View Insider Buying and Selling for Baxalta.

How do I buy Baxalta stock?

Shares of Baxalta can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Baxalta stock cost?

One share of Baxalta stock can currently be purchased for approximately $46.02.

Analyst Ratings

Consensus Ratings for Baxalta (NYSE:BXLT) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Baxalta (NYSE:BXLT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/6/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
12/9/2015Barclays PLCBoost Price TargetEqual Weight$38.00 -> $40.00N/AView Rating Details
10/27/2015William BlairReiterated RatingBuyN/AView Rating Details
8/11/2015Credit Suisse Group AGBoost Price TargetOutperform$37.00 -> $42.00N/AView Rating Details
7/21/2015JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
7/16/2015Citigroup IncInitiated CoverageBuy$40.00N/AView Rating Details
7/13/2015Deutsche Bank AGInitiated CoverageHold$32.00N/AView Rating Details
7/6/2015Goldman Sachs Group IncInitiated CoverageHoldN/AView Rating Details
7/1/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$35.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for Baxalta (NYSE:BXLT)
Earnings by Quarter for Baxalta (NYSE:BXLT)
Earnings History by Quarter for Baxalta (NYSE:BXLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/28/2016Q116$0.46$0.47$1.47 billion$1.50 billionViewN/AView Earnings Details
2/16/2016Q415$0.56$0.57$1.71 billion$1.80 billionViewN/AView Earnings Details
10/29/2015Q315$0.49$0.56$1.51 billion$1.60 billionViewListenView Earnings Details
7/30/2015Q215$0.50$0.40$1.41 billion$1.47 billionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Baxalta (NYSE:BXLT)
Current Year EPS Consensus Estimate: $2.19 EPS
Next Year EPS Consensus Estimate: $2.54 EPS


Current Dividend Information for Baxalta (NYSE:BXLT)
Most Recent Dividend:7/1/2016
Dividend Yield:0.00%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:0.00% (Based on This Year's Estimates)
0.00% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Baxalta (NYSE:BXLT)

Dividend History by Quarter for Baxalta (NYSE:BXLT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Baxalta (NYSE:BXLT)
Insider Trades by Quarter for Baxalta (NYSE:BXLT)
Institutional Ownership by Quarter for Baxalta (NYSE:BXLT)
Insider Trades by Quarter for Baxalta (NYSE:BXLT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/24/2016Albert P L StrouckenDirectorSell5,660$39.98$226,286.80View SEC Filing  
2/25/2016Blake E DevittDirectorBuy5,900$39.17$231,103.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Baxalta (NYSE:BXLT)
Latest Headlines for Baxalta (NYSE:BXLT)
DateHeadline logoAlexion: Look Out Below! - May 23 at 1:00 PM logoJulian Robertson Buys Adobe and Sells Apple in 1st Quarter - Nasdaq - May 16 at 4:10 PM logoBaxalta (BXLT) Receiving Somewhat Positive Press Coverage, Report Finds - May 4 at 1:01 AM logoBaxalta (BXLT) Receives Daily Media Impact Rating of 0.56 - April 30 at 10:18 AM logoTakeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation - January 9 at 5:14 PM logoCTI Biopharma stock revived after FDA ruling, reverse stock split - January 6 at 9:27 PM logoShire reiterates full-year guidance after in-line Q3 - November 1 at 4:02 PM logoHouston cancer company closes additional funding - Houston Business Journal - October 10 at 3:54 PM logoShire plc -- Moody's assigns Baa3 to Shire's sr. notes; stable outlook - September 16 at 3:56 PM logoTracking Stephen Mandel's Lone Pine Capital Portfolio - Q2 2016 Update - Seeking Alpha - August 25 at 4:05 PM logoForm N-PX WELLS FARGO FUNDS TRUST For: Jun 30 - - August 25 at 8:54 AM logoTracking Tweedy Browne Portfolio - Q2 2016 Update - Seeking Alpha - August 12 at 12:40 PM logoBaxter International Inc. -- Moody's rates Baxter's new notes Baa2; outlook stable - August 10 at 3:28 PM logoApple-Twitter: Why Not? - Seeking Alpha - August 7 at 3:59 PM logoShire Says Baxalta Combination to Boost Profit and Sales - August 2 at 8:51 AM logoShire upgrades Baxalta cost savings after Q2 earnings beat - August 2 at 8:51 AM logoShire lifts earnings and Baxalta cost saving targets - August 2 at 8:51 AM logo[$$] Shire Earnings: What to Watch - August 1 at 4:00 PM logo3 Mutual Funds Focusing on Arbitrage Profits (MERFX, ARBFX) - July 28 at 10:00 AM logoDan Loeb's Third Point tells why investing is like 'Game of Thrones' - July 26 at 8:26 PM logoBaxter Beats Earnings Estimates, Raises Full-Year Guidance - July 26 at 7:11 AM logoTweedy Browne Global Value Fund Makes Trades Around the World - Nasdaq - July 13 at 3:59 PM logoBiotech ETF IBB Short Squeeze May Be Ahead - Seeking Alpha - July 12 at 4:05 PM logoTop 3 Stocks Hedge Funds Bought in Q1, 2016 - June 21 at 10:00 AM logoTop 3 Stocks Hedge Funds Bought in Q1, 2016 - June 21 at 10:00 AM logoAre Hedge Funds Trying to Catch the Falling Knife? (AMZN, NFLX) - June 19 at 3:52 PM logoFitch Downgrades Baxalta to 'BBB'; Withdraws Ratings - June 7 at 12:17 PM logoShire plc -- Moody's downgrades Baxalta to Baa3; stable outlook - June 6 at 1:02 PM



Baxalta (BXLT) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff